⌕
Zoetis · ZTS · NYSE
Tenet 59 · Mixed
Compare
$83.48−1.08%At closeTenet 59 · Mixed
$83.48−0.91 (−1.08%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$83.03−0.45 (−0.54%)
After hours: Nov 17, 2026, 7:52 PM ET

Zoetis (ZTS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ZTS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 16, 2026 · 11:13 ET
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

ZTS −1.1% todayRead at source ↗
● Defense WorldNov 16, 2026 · 04:33 ETEARNINGS EXPECTED BY FEB 16
Eurizon Capital SGR S.p.A. Sells 75,462 Shares of Zoetis Inc. $ZTS

Eurizon Capital SGR S.p.A. lowered its position in shares of Zoetis Inc. (NYSE: ZTS) by 48.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund…

ZTS −1.1% todayRead at source ↗
● Defense WorldNov 14, 2026 · 03:30 ETEARNINGS EXPECTED BY FEB 16
Zoetis Inc. $ZTS Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lowered its stake in Zoetis Inc. (NYSE: ZTS) by 24.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutiona…

ZTS −1.1% todayRead at source ↗
● Zacks Investment ResearchNov 12, 2026 · 10:51 ET
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.…

ZTS −1.1% todayRead at source ↗
● Business WireNov 11, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.…

ZTS −1.1% todayRead at source ↗
● Business WireNov 10, 2026 · 07:30 ET
Zoetis to Participate in the Jefferies Global Healthcare Conference in London

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jeff…

ZTS −1.1% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 16
ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook

Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.…

ZTS −1.1% todayRead at source ↗
● MarketBeatNov 8, 2026 · 17:14 ETEARNINGS EXPECTED BY FEB 16
What Zoetis (ZTS) Said on Its Q3 Earnings Call

Zoetis NYSE: ZTS reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal health company narrow…

ZTS −1.1% todayRead at source ↗
● Seeking AlphaNov 6, 2026 · 09:18 ET
Zoetis: Quality Company Trading Cheap

Zoetis Inc., formerly Pfizer's veterinary arm, is a global leader in animal pharmaceuticals and diagnostics. ZTS generates most revenue from companion animal products, with approximately 30% from livestock healthcare sol…

ZTS −1.1% todayRead at source ↗
● Seeking AlphaNov 6, 2026 · 05:24 ETEARNINGS EXPECTED BY FEB 16
Zoetis Inc. (ZTS) Q3 2026 Earnings Call Transcript

Zoetis Inc. ( ZTS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Mathieu Aussermeier Kristin Peck - CEO & Director James Saccaro - Executive VP, CFO & COO Conference Call Participants Christoph…

ZTS −1.1% todayRead at source ↗
● The Motley FoolNov 5, 2026 · 21:47 ETEARNINGS EXPECTED BY FEB 16
Zoetis: 3 Key Takeaways for Long-Term Investors

Zoetis's organic operational revenue fell 1% in the third quarter. Global livestock revenue rose 7% to $797 million.…

ZTS −1.1% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 14:30 ETEARNINGS EXPECTED BY FEB 16
ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up

Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.…

ZTS −1.1% todayRead at source ↗
● ReutersNov 5, 2026 · 13:55 ET
Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall

Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall…

ZTS −1.1% todayRead at source ↗
● BenzingaNov 5, 2026 · 13:15 ETEARNINGS EXPECTED BY FEB 16
Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy

Zoetis Inc. (NYSE:ZTS) reported third-quarter adjusted earnings of $1.75 per share, beating the consensus of $1.51.…

ZTS −1.1% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 16
Zoetis (ZTS) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the …

ZTS −1.1% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 09:15 ETEARNINGS EXPECTED BY FEB 16
Zoetis (ZTS) Q3 Earnings and Revenues Top Estimates

Zoetis (ZTS) came out with quarterly earnings of $1.75 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.7 per share a year ago.…

ZTS −1.1% todayRead at source ↗
● Business WireNov 5, 2026 · 07:00 ETEARNINGS EXPECTED BY FEB 16
Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026. "Our third-quarter performa…

ZTS −1.1% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 00:31 ETEARNINGS EXPECTED BY FEB 16
Zoetis: Near-Term Expectations More Achievable, Long Growth Runway Undervalued

Zoetis is emerging from a period of underperformance, with market expectations for Q3 and Q4 set notably low. Consensus and management guidance anticipate revenue and EPS declines, but these expectations appear beatable …

ZTS −1.1% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 11:16 ETEARNINGS EXPECTED BY FEB 16
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect

ZTS heads into Q3 earnings with international growth, livestock strength and demand for key companion animal products offsetting U.S. market challenges.…

ZTS −1.1% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 10:16 ETEARNINGS EXPECTED BY FEB 16
Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key Metrics

Evaluate the expected performance of Zoetis (ZTS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.…

ZTS −1.1% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 19:16 ET
Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note

In the most recent trading session, Zoetis (ZTS) closed at $78.8, indicating a +1.29% shift from the previous trading day.…

ZTS −1.1% todayRead at source ↗
● Business WireOct 20, 2026 · 16:42 ETCOMPANY'S OWN WORDS
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.…

ZTS −1.1% todayRead at source ↗
● Business WireOct 13, 2026 · 07:30 ET
Zoetis Appoints Iris Knobloch to its Board of Directors

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience ac…

ZTS −1.1% todayRead at source ↗
● Business WireOct 8, 2026 · 16:15 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Zoetis Declares Fourth Quarter 2026 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, …

ZTS −1.1% todayRead at source ↗
● Business WireOct 6, 2026 · 07:30 ET
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows that not all heartwor…

ZTS −1.1% todayRead at source ↗
● Business WireSep 24, 2026 · 07:30 ETEARNINGS EXPECTED BY FEB 16
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive…

ZTS −1.1% todayRead at source ↗
● Business WireSep 2, 2026 · 07:30 ET
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will…

ZTS −1.1% todayRead at source ↗

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just ZTS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.